#95 Landmark Clinical Evidence
Peer-reviewed human research with direct implications for cannabis medicine practice.
I don’t see a summary provided for the article. Please share the summary text so I can write the 2-3 sentences explaining its clinical relevance.
This review examines formulation and fabrication strategies for oral mucosal cannabinoid delivery systems, which offer potential advantages over traditional ingestion by enabling faster onset through direct absorption across the buccal and sublingual mucosa. Current approaches include sublingual oils and sprays, oromucosal films, lozenges, and novel systems such as nanoparticle-based formulations and mucoadhesive patches designed to improve bioavailability and patient compliance. The oral mucosal route addresses key clinical limitations of conventional cannabis products, including variable absorption rates, delayed onset (1-2 hours for edibles), and inconsistent plasma levels that complicate dosing in therapeutic contexts like chronic pain and epilepsy. Barriers to clinical development include poorly characterized cannabinoid permeability across oral tissues, lack of standardized in vitro and in vivo testing methods, and regulatory uncertainty around formulation classification and approval pathways. Clinicians should recognize that oral mucosal formulations represent an emerging option that could provide more predictable pharmacokinetics and faster symptom relief compared to standard edibles, though evidence comparing efficacy and safety across different delivery systems remains limited. Until rigorous clinical trials and regulatory frameworks establish standards for these products, prescribers should counsel patients about the preliminary nature of oral mucosal cannabinoid formulations and advocate for transparent labeling and quality assurance standards.
“The real clinical barrier we face isn’t the science of oral mucosal cannabinoid delivery—it’s that most patients still can’t access properly formulated, standardized products because pharmacy infrastructure hasn’t caught up with the pharmacology. Until we have the same quality control for sublingual cannabinoids that we do for any other medication, we’re asking patients to experiment with their own dosing.”
💊 As cannabis products increasingly enter mainstream medical practice, understanding optimal delivery methods becomes clinically relevant for maximizing therapeutic efficacy and minimizing adverse effects. This review of oral mucosal delivery systems highlights emerging formulation approaches that could improve cannabinoid bioavailability and onset of action compared to traditional smoking or standard oral ingestion, potentially offering patients more predictable dosing and faster symptom relief. However, clinicians should recognize that most of these advanced delivery technologies remain in preclinical or early clinical stages, with limited head-to-head efficacy comparisons and safety data in actual patient populations. Additionally, substantial individual variability in cannabinoid metabolism, variable product potency in non-regulated markets, and the complex pharmacology of cannabis compounds mean that laboratory-optimized formulations may not translate predictably to clinical practice. Given these gaps, practitioners should counsel patients using cannabis that evidence-based dosing guidance remains limited, encourage use of standardized pharmaceutical
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: